PARP1 and cholangiocarcinoma: Studying the effects of PARP1 inhibition in the other BAP1-mutant malignancies, such as renal cell carcinoma and cholangiocarcinoma, would be especially important, since cancers also have little beneficial therapy once initial resection has failed [8].